Going to MARS may shorten our patient's survival
- PMID: 39675416
- DOI: 10.1016/j.jtcvs.2024.12.006
Going to MARS may shorten our patient's survival
Keywords: chemotherapy; immunotherapy; pleural mesothelioma; pleurectomy decortication; surgery.
Conflict of interest statement
Conflict of Interest Statement R.T.R. reported grant funding from the National Institutes of Health (R37, R01, U01, U24) and the DeGregorio Family Foundation; clinical trial support from AstraZeneca and Genentech; Vice President of the Board of Directors for the Meso Foundation; and speakers' bureau for Merck. S.B. reported consulting/advisory board service for BD, Livsmed, and Karl Storz; speaking fees from AstraZeneca, Bristol Myers Squibb, KLS Martin, and Roche; and funding for studies from Janssen, Bristol Myers Squibb, AstraZeneca, Achilles Therapeutics, and BD. M.d.P. reported consulting fees from AstraZeneca, BMS, Merck, and Roche. P.A.U.F. reported advisory board service and honoraria for lectures from AstraZeneca and Medtronic. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
Publication types
LinkOut - more resources
Miscellaneous